# A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

> **NCT06952465** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 2000 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Deucravacitinib
- **BIOLOGICAL:** Any biologic treatment for psoriasis

## Key facts

- **NCT ID:** NCT06952465
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2031-11-30
- **Final completion:** 2031-11-30
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952465, "A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06952465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*